Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03601078
Recruitment Status : Recruiting
First Posted : July 26, 2018
Last Update Posted : July 24, 2019
Sponsor:
Information provided by (Responsible Party):
Celgene

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 12, 2025
Estimated Study Completion Date : March 12, 2025